US-guided RFA an effective treatment for benign thyroid nodules

  • Lee GM & al.
  • Endocrine
  • 19 Dec 2018

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Ultrasound (US)-guided radiofrequency ablation (RFA) is associated with >90% therapeutic success rate in patients with benign thyroid nodules, with comparable results in patients with predominantly solid (PS) vs predominantly cystic (PC) lesions.

Why this matters

  • Few studies have addressed whether solid vs cystic lesion status affects the outcomes of US-guided RFA.

Key results

  • After the first ablation, rates of therapeutic success (volume reduction >50% at 6 months) were 78.9% in patients with PC lesions and 78.2% in patients with PS lesions (P=.439).
  • After the final ablation, rates of therapeutic success were 91.4% in patients with PC lesions and 93.4% in patients with PS lesions (P=.148).
  • The most common complications were localized edema (1.9% in PC group; 1.3% in PS group), transient voice change (0.5% in PC group; 0.3% in PS group), and infection (0.3% in PC group; 0.3% in PS group).
  • Small thyroid nodule volume (

Study design

  • 1000 patients with 1619 thyroid nodules were treated with US-guided RFA and analyzed for outcomes.
  • Funding: Korea University.

Limitations

  • Retrospective analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit